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Summary The matrix metalloproteinase inhibitor batimastat was administered to a human colorectal cancer
ascites model, which was initiated by injection of C170HM2 cells into the peritoneal cavity of SCID mice and
resulted in solid tumour deposits and ascites formation. The cell line expressed both the 72 and 92 kDa forms
of gelatinase by zymography. Batimastat administered from day 0 (40 mg kg-1) reduced the volume of ascites
to 21% ofcontrol in mice treated from day 0 (P<0.002) but not day 10. Formation of solid peritoneal deposits
was significantly reduced to 77% of vehicle control when batimastat was administered from day 0 (P<0.01)
and 69% of control when administered from day 10 (P<0.05). Thus, batimastat has the ability to reduce the
volume of ascites forming in SCID mice injected intraperitoneally with the human colorectal cell line,
C170HM2, when administered from day 0 but not from day 10. Solid peritoneal tumour deposits were
significantly reduced in both treatment groups, highlighting the therapeutic potential of batimastat in this
clinical condition.
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A large body of evidence now suggests that matrix
metalloproteinases (MMPs) play a role in the metastasis of
tumour cells (Brown, 1993). Secretion of these enzymes by
both normal and malignant cells is in the form of a latent
precursor, which is activated by removal of an amino
terminal domain (Stetler-Stevenson et al., 1989). These
enzymes are implicated in the breakdown of extracellular
matrix and vascularisation, which are both critical for
successful metastasis, and recent clinical studies have shown
MMP to play a role in the spread of human tumour cells
(Brown et al., 1993; Davies et al., 1993).
The role of individual enzymes from the MMP family, in
both the growth and metastatic spread of colorectal tumours,
has been investigated. Activity of type I fibrillar collagenase, a
member ofthe MMP family, has been shown to correlate with
histological grade (van der Strappen, 1990). The 72 kDa
gelatinase, which breaks down type IV collagenase of base-
ment membrane, correlates with tumour progression, and
mRNA studies have revealed the presence ofthis enzyme in the
tissue stroma adjacent to the invasive edge of the cancer
(D'Errico et al., 1991; Poulson et al., 1992). The 92 kDa form
ofgelatinase has been demonstrated by immunocytochemistry
to be widespread in colorectal carcinoma, especially in tumours
of advanced stage (Jeziorska et al., 1994). In the same study,
expression ofthe enzyme at specific sites in the tumour has been
shown to be inversely related to the localisation of type IV
collagen. Furthermore, the 92 kDa gelatinase is elevated in the
plasma ofcolon cancer patients (Zucker et al., 1993). In a study
evaluating stromelysins 1 and 2 and matrilysin (PUMP-1)
expression in colorectal cancer, the mRNA ofthe latter enzyme
was expressed in 75% ofcolon carcinomas, whereas the mRNA
of the former was not detected (McDonnell et al., 1991). In a
recent study, stromelysin 3 mRNA was overexpressed in
primary colorectal adenocarcinomas and liver metastases and
expression was shown in stromal fibroblasts adjacent to the
neoplastic lesions (Porte et al., 1995).
A study examining collective expression of gelatinases and
matrilysin suggested that the latter may participate early in
tumour progression, whereas the former enzymes, in
conjunction with matrilysin and other members of the
MMP family, may mediate events occurring later in the
progressive cascade (Newell et al., 1994).
The synthetic metalloproteinase inhibitor, batimastat, has
broad spectrum and potent activity against many members of
the MMP family (Brown, 1993) and has been shown to inhibit
the metastatic spread of the B16 murine melanoma (Chirivi et
al., 1994) and the lung and liver colonisation of the human
colorectal tumours, AP5LV and C170HM2 respectively
(Watson et al., 1995). In addition, the agent has been shown
to inhibit tumour growth in an ovarian ascites model (Davies et
al., 1993). Owing to the pharmacokinetics of the drug, it has
potential therapeutic use in cases of malignant ascites and has
been evaluated in clinical patients with ascites of malignant
origin (SL Parsons et al. unpublished data). This study sets out
to determine the direct effects ofbatimastat on tumour growth
in an aggressive ascites model initiated by a gastrointestinal
cancer cell line.
Materials and methods
Cell line
C170HM2 ascites is a human colorectal tumour cell line
selected to yield an end point of ascites after administration
of the parental line, C17OHM2 (Watson et al., 1993), into the
peritoneal cavity of severe combined immunodeficient (SCID)
mice. This cell line was derived in the Cancer Studies Unit,
Department of Surgery, Nottingham.
Batimastat
The chemical name is [4(N-hydroxyamino)-2R-isobutyl-35-
(thienyl-thiomethyl)-succinyl]-L-phenylalanine-N-methylamide
and it has a molecular weight of 478 kDa. Batimastat has
been shown to inhibit the following members of the MMP
family: collagenase, stromelysin, the 72 and 92 kDa
gelatinase and matrilysin with a 50% inhibitory concentra-
tion for all enzymes (IC50) in the 1 -20 nM range.
Initiation of the C17OHM2 ascites model
C170HM2 ascites cells were maintained in vitro in RPMI-
1640 culture medium (Gibco, Paisley, UK) containing 10%
(v/v) heat-inactivated fetal calf serum (FCS; Sigma, Poole,
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UK) at 37°C in 5% carbon dioxide and humidified
conditions. Cells from semiconfluent monolayers were
harvested with 0.025% EDTA and suspended in sterile
phosphate-buffered saline (PBS, pH 7.4) at a cell concentra-
tion of 5 x 106 ml-' and a 1 ml volume was injected into the
peritoneal cavity of 60 female SCID mice (Cancer Studies
Unit, University of Nottingham, UK, 6-10 weeks of age).
Animals were kept in sterile isolation and were fed and
watered ad libitum and divided into the following groups:
Group 1 Vehicle control [PBS, containing 0.01% (v/v) Tween-
80 (PBS-Tween)], 0.3 ml per animal administered intraper-
itoneally (i.p.) every third day from day 0 until
termination of the experiment.
Group2 Batimastat suspended at a concentration of
2.5 mg ml-' in PBS-Tween, 0.3 ml per animal
(40 mg kg-') administered i.p. every third day from 0
until termination.
Group3 PBS-Tween vehicle administered i.p. every third day
from day 10.
Group4 Batimastat administered i.p. every third day from
day 10 (40 mg kg-1).
To rule out non-specific effects caused by drug and tumour
cells being administered by the same route, treatment was
delayed until day 10 in groups 3 and 4. At this time tumour
nodules were just palpable, indicating establishment of
tumour growth.
Animals were weighed and their clinical condition was
assessed once weekly. Animals were terminated at onset of
ascites formation or when peritoneal tumour burden was
large and weight loss approached 10% of the whole body
weight. This was shown to occur at day 28. The UK Co-
ordinating Committee for Cancer Research guidelines were
adhered to throughout all animal experimentation.
At termination, ascites volume was measured and assessed
for both tumour cell density and viability. The total number
of viable cells present within the peritoneal cavity was
calculated from the above parameters and solid tumour
deposits were dissected and weighed.
Zymography
The metalloproteinase enzyme profiles of C17OHM2 ascites
cells growing both in vitro and freshly harvested from the
peritoneal cavity were determined by the method of
zymography, which was performed according to the method
of Brown et al. (1993). The positive control was supernatant
harvested from the HT1080 human fibrosarcoma cell line,
which had been treated with 1 mM APMA (Sigma). Ascites
samples were spun down and 10 ,ul of supernatant collected
and added to 90 ,l of sample buffer. The resultant solution
was vortexed and 25 jl added to the zymogram wells.
Electrophoresis was performed and the gel was washed in
detergent and then incubated overnight in developing buffer.
The gel was then stained with colloidal Coomassie blue and
dried using the gel dry apparatus (Novex, Oxford, UK).
Clear bands represent the 92 and 72 kDa gelatinase as
indicated by the standards in lane 1.
Statistical analysis
This was performed by a chi-squared test and a Student's t-
test, where appropriate, using the SPSS program for the IBM
PC. A P-value of <0.05 was considered to indicate statistical
significance.
Results
Zymography
Figure 1 shows a typical gel derived from C17OHM2 ascites
cell extracts. The 92 and 72 kDa gelatinase enzymes were
detected both in cells grown in vitro and in cells freshly
derived from the peritoneal cavity.
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92 kDa >
72 kDa >
1 2 3
Figure 1 Zymogram of C170HM2 ascites cells. Lane 1, super-
natant from HT1080 cells showing the 72 and 92kDa gelatinase
bands; lane 2, C170HM2 ascites cells grown in vitro; lane 3,
C170HM2 ascites cells directly harvested from the peritoneal
cavity.
Table I Effect of batimastat on the onset of ascites in SCID mice
bearing the human colorectal line, C17OHM2ASC
Number of mice with ascites (%)
Vehicle control 15/15 (100)
Day 0
Batimastat 8/15 (53)*
Day 0
Vehicle control 14/15 (93)
Day 10
Batimastat 10/15 (67)
Day 10
*P<0.07, chi-squared test.
In vivo therapy
Table I shows the incidence of C17OHM2-induced ascites in
mice treated from day 0 with batimastat and those with
treatment delayed until day 10. Batimastat treatment from day
0 reduced the incidence of ascites from 100% in the matching
vehicle control to 53% in the treated group, whichjust failed to
reach statistical significance (P=0.07, chi-squared test). When
treatment was delayed until day 10, the incidence was reduced
from 93% to 67%, which was not significantly different.
The volume of accumulated ascites is shown in Figure 2a
and b. Figure 2a includes all experimental animals and Figure
2b includes only mice developing ascites. With all experimental
animals included, mice treated with batimastat from day 0 had
significantly reduced volumes ofascites (21% ofcontrol) when
compared with the vehicle control, which was statistically
significant (P<0.001, Student's t-test). However, a significantly
different ascites volume was not achieved when batimastat was
administered from day 10 (Figure 2a). When including only
experimental mice that accumulated ascites, those treated with
batimastat from day 0 had a significantly reduced volume when
compared with the vehicle controls (P<0.002, Student's t-test),
but not when administered from day 10 (Figure 2b).
Table II further summarises the ascites formation in the
four groups of experimental animals (with only animals
accumulating ascites included). Days to ascites was not
significantly altered in both treatment groups when compared
with the corresponding controls.
Viability of the cells in the ascites fluid in all groups was
high (>90%), with no statistically significant difference seen
between the four groups (Table II). The cell density of the
accumulated ascites was also not significantly different
between the four treatment groups, ranging from 1.6 x 106
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Peritoneal tumour weights are shown in Figure 3. There
was a significant reduction in peritoneal tumour weight in
both batimastat-treated groups; 77% of control for treatment
from day 0, P<0.01 and 69% of control following treatment
from day 10, P<0.05.
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There was no significant difference between the mean
animal weights of the treated vs the vehicle control-treated
animals (data not shown).
Discussion
The role of matrix metalloproteinases in colorectal cancer
appears to be multifactorial and thus warrants the use of
broad spectrum metalloproteinase inhibitors, such as batima-
stat, as potential therapeutic agents.
Previous studies in metastatic models have shown
batimastat to possess antimetastatic activity against a
number of different tumour types. Haematogenous spread
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inhibited by batimastat, resulting in a reduction in the
number of lung nodules; investigations indicated this was due
to an effect on the extravasation of tumour cells in the lung
(Chirivi et al., 1994). In a second spontaneous metastasis
model, involving orthotopic implantation of a human
colorectal tumour, batimastat reduced the growth of both
the primary tumour ana seconuary spreaa, resulting in an
enhanced survival of the experimental animals (Wang et al.,
1 1994). Finally, in a model which evaluated liver invasion of a
human colorectal tumour line, invasive growth was inhibited
by batimastat treatment. Tumours that did form had
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Figure 2 The mean ascites volume of SCID mice bearing the
human ascitic line, C17OHM2, in the following groups: vehicle
control administered from day 0; batimastat administered from
day 0 (40mg kg-', i.p.); vehicle control administered from day
10; batimastat administered from day 10 (40mgkg-1, i.p.). (a) In
all experimental mice; (b) only mice in which ascites accumulated.
Statistical assessment was by the Student's t-test. *P<0.001.
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Figure 3 The peritoneal tumour weights of SCID mice bearing
the human ascitic line, C17OHM2, in the following groups: vehicle
control administered from day 0; batimastat administered from
day 0 (40mgkg-, i.p.); vehicle control administered from day 10;
batimastat administered from day 10 (40mgkg-, i.p.). Statistical
assessment was by Student's t-test. *P<0.01, **P<0.05 from
respective controls.
Table II A summary of the effect of batimastat administration on ascites formation in SCID mice bearing the human colorectal
line, C17OHM2ASC
Days to Ascites cell Ascites density
ascitesa viability (%)a (cellsml-)a
Vehicle control 25.9 93.0 2.3 x 106
DayO (1.5) (6.2) (1.6x 106)
Batimastat 28 90.5 3.2x 106
DayO (0) [NS] (9.6) [NS] (9.2 x 105) [NS]
Vehicle control 26.2 92.3 2.5 x 106
DaylO (1.83) (5.9) (1.8x 106)
Batimastat 27.3 90.0 1.6 x 106
Day 10 (0.88) [NS] (8.6) [NS] (8.1 x 105) [NS]
Significance values are shown in square brackets. aMean values are shown (standard deviation is in brackets). NS, not significant as
assessed by Student's t-test.
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advanced necrosis, indicative ofa reduction in vascularisation
(Watson et al., 1995). Thus, although the mechanisms of
action of batimastat have not been confirmed, the studies
performed so far indicate that the drug may inhibit tumour
growth, possibly by preventing new invasive growth and by
inhibiting neovascularisation.
The present study has evaluated the effect of batimastat on
a human colorectal ascites model. A similar study, performed
in a human ovarian ascites model in nude mice (Davies et al.,
1993), showed batimastat to induce a resolution of ascites
and an enhancement of survival. Histological observations
revealed that, following treatment, free-floating ascitic cells
had reverted to solid tumours surrounded by a capsule of
host tissue. Batimastat was postulated to induce its anti-
tumour effect by promoting the synthesis of stromal
connective tissue by blocking the equilibrium between
synthesis and degradative pathways.
Clinically, batimastat has been used to treat malignant
ascites from a gastrointestinal (GI) origin. In a recent study
by SL Parsons et al. (unpublished data), batimastat showed
encouraging results in malignant ascites. As GI malignant
ascites is a more aggressive condition than that of ovarian
ascites, it was decided to investigate the inhibitory effects of
batimastat on tumour growth in an aggressive in vivo GI
ascites model.
In the present study, batimastat inhibited ascites formation
in 47% of the animals and reduced the accumulation in the
remaining animals, when given from the time of tumour cell
injection. Solid peritoneal tumour growth was also reduced.
The results from the group given batimastat 10 days after cell
injections indicates that batimastat is unable to inhibit ascites
formation but can affect the growth of solid tumour deposits.
In the GI ascites model free-floating ascitic cells were still
present following batimastat treatment, unlike the ovarian
ascites model described by Davies et al. (1993). This could
reflect differences in tumour growth rate in the two models.
I-n the present study, inhibition of solid tumour growth was
equivalent when batimastat was given from day 0 and day 10.
This indicates that batimastat inhibition occurred at > 10
days of tumour growth, possibly during the phase when
neovascularisation may have been maximal. In a previous
model it has been shown that batimastat has the potential to
inhibit angiogenesis (Taraboletti et al., 1995).
It is known that these effects could not be attributed to
non-specific cytotoxic effects on the cells, as a wide range of
batimastat concentrations (0.01-5 ,ug ml-') has previously
been shown not to affect the in vitro proliferation of
Cl7OHM2 cells (Watson et al., 1995). In addition, in the
liver invasive model involving C170HM2 in nude mice
(Watson et al., 1995), an inactive isomer of batimastat,
BB1268, had no inhibitory effects on tumour growth. In fact
the agent stimulated tumour growth, which was postulated to
be caused by non-specific blockade of the reticuloendothelial
system, resulting in enhanced accumulation of tumour cells
within the peritoneal cavity. Thus, any therapeutic effects
seen both in the liver-invasive model and in the present
ascites model is unlikely to be attributable to administration
of the drug and tumour cells both directly into the peritoneal
cavity.
The role of MMPs in ascites formation is unclear but, in
accordance with Davies et al. (1993), the present study does
provide additional evidence that metalloproteinases are
involved in maintaining the stromal equilibrium necessary
to ensure that ascitic cells remain in a suspension form. In
addition, as volume was suppressed greatly by batimastat in
the present study, it may be that metalloproteinases have a
role to play in vascular permeability mediating fluid
accumulation in the peritoneal cavity, which may provide a
source of nutrients for the tumour cells present. One agent
involved in this process is vascular permeability factor, which
is abundant in tumour ascites fluid (Senger et al., 1983) and is
secreted by a number of human tumour types (Senger et al.,
1986), including colorectal (Lobb et al., 1985). It is, therefore,
possible that MMP inhibitors may either directly or indirectly
inhibit secretion of tumour-associated permeability factors,
which would explain their potent therapeutic effect in both
the ovarian and the present colorectal ascites model.
Thus, batimastat appears to be therapeutically active in a
colorectal cancer ascites model by preventing ascites
formation and reducing the solid tumour burden within the
peritoneal cavity. These findings have important implications
for the therapeutic potential of batimastat in this area.
Acknowledgements
The authors would like to acknowledge the technical assistance of
Ms Marian Exton and Mr David Crosbee, and Ms Debbie
Milanowska for typing the script.
References
BROWN PD. (1993). Matrix metalloproteinase inhibitors: a new class
of anti-cancer agents. Curr. Drugs Opin. Invest., 2, 617-626.
BROWN PD, BLOXIDGE RE, STUART NS, GATTER KC AND
CARMICHAEL J. (1993). Association between expression of
activated 72-kilodalton gelatinase and tumor spread in non-
small-cell lung carcinoma. J. Natl Cancer Inst., 85, 574.
CHIRIVI RGS, GAROFALO A, CRIMMIN MJ, BAWDEN LJ, STOP-
PACCIARO A, BROWN P AND GIAVAZZI R. (1994). Inhibition of
the metastatic spread and growth of B16-BL6 murine melanoma
by a synthetic matrix metalloproteinase inhibitor. Int. J. Cancer,
58, 460-464.
DAVIES R, BROWN PD, EAST N, CRIMMIN MJ AND BALKWILL R.
(1993). Matrix metalloproteinase inhibitor decreases tumour
burden and survival of mice bearing human ovarian carcinoma
xenografts. Cancer Res., 53, 2087-2091.
D'ERRICO A, GARBISA S, LIOTTA LA, CASTRONOVO V, STETLER-
STEVENSON WG AND GRIGIONI WF. (1991). Augmentation of
type IV collagenase, laminin receptor, and Ki67 proliferation
antigen associated with human colon, gastric and breast
carcinoma progression. Modern Pathol., 4, 239-246.
JEZIORSKA M, HABOUBI NY, SCHOFIELD PF, OGATA Y, NAGASE
H AND WOLLEY DE. (1994). Distribution ofgelatinase B (MMP-
9) and type IV collagen in colorectal carcinoma. Int. J. Colorectal
Dis., 9, 141-148.
LOBB RR, KEY ME, ALDERMAN EM AND FETT JW. (1979). Partial
purification and characterization ofa vascular permeability factor
secreted by a human colon adenocarcinoma cell line. Int. J.
Cancer, 36, 473-478.
MCDONNELL S, NAVRE M, COFFEY RJ AND MATRISIAN LM.
(1991). Expression and localization of matrix metalloproteinase
pump-1 (MMP-7) in human gastric and colon carcinomas. Mol.
Carcinogen., 4, 527-533.
NEWELL KJ, WITTY JP, RODGERS WH AND MATRISIAN LM.
(1994). Expression and localization ofmatrix-degrading metallo-
proteinases during colorectal tumorigenesis. Mol. Carcinogen.,
10, 199-206.
PORTE H, CHASTRE E, PREVOT S, NORDLINGER B, EMPEREUR S,
BASSET P, CHAMBON P AND GESPACH C. (1995). Neoplastic
progression of human colorectal cancer is associated with
overexpression of the stromelysin-3 and BM-40/Sparc genes.
Int. J. Cancer, 64, 70-75.
POULSOM R, PIGNATELLI M, STETLER-STEVENSON WG, LIOTTA
LA, WRIGHT PA, JEFFERY RW, LONGCROFT JM, ROGERS L
AND STAMP G. (1992). Stromal expression of 72kDa type IV
collagenase (MMP-2) and TIMP-2 nRNAs in colorectal
neoplasia. Am. J. Pathol., 141, 389-396.Effect of batimastat in colorectal cancer
SA Watson et al
1358
SENGER DR, GALLI SJ, DVORAK AM, ERRUZZI CA, HARVEY VS
AND DVORAK HF. (1983). Tumor cells secrete a vascular
permeability factor that promotes accumulation of ascites fluid.
Science, 219, 983-985.
SENGER DR, PERRUZZI CA, FEDER J AND DVORAK HF. (1986). A
highly conserved vascular permeability factor secreted by a
variety of human and rodent tumor cell lines. Cancer Res., 46,
5629-5632.
STETLER-STEVENSON WG, DRUTZSCHE HC AND LIOTTA LA.
(1989). Tissue inhibitor of metalloproteinase (TIMP-2). A new
member ofthe metalloproteinase inhibitor family. J. Biol. Chem.,
264, 1353- 1356.
TARABOLETTI G, GAROFALO A AND BELOTTI D. (1995).
Inhibition of angiogenesis and murine hemangioma growth by
batimastat, a synthetic inhibitor of matrix metalloproteinases. J.
Natl Cancer Inst., 87, 293-298.
VAN DER STRAPPEN JWJ, HENDRIKS T AND WOBBES T. (1990).
Correlation between collagenolytic activity and grade of
histological differentiation in colorectal tumours. Int. J. Cancer,
45, 1017-1078.
WANG X, FU X, BROWN PD, CRIMMIN JM AND HOFFMAN RM.
(1994). Matrix metalloproteinase inhibitor BB94 (Batimastat)
inhibits human colon tumour growth and spread in a patient-like
orthotopic model in nude mice. Cancer Res., 54, 4726-4728.
WATSON SA, MORRIS TM, ROBINSON G, CRIMMIN MJ, BROWN PD
AND HARDCASTLE JD. (1995). Inhibition or organ invasion by
the matrix metalloproteinase inhibitor batimastat (BB-94) in two
human colon carcinoma metastasis models. Cancer Res., 55,
3629-3633.
WATSON SA, MORRIS TM, CROSBEE DM AND HARDCASTLE JD.
(1993). A hepatic invasive human colorectal xenograft model.
Eur. J. Cancer, 12, 1740- 1745.
ZUCKER S, LYSIK RM, ZARRABI MH AND MOLL U. (1993). Mr
92,000 type IV collagenase is increased in plasma ofpatients with
colon cancer and breast cancer. Cancer Res., 53, 140-146.